PT-141 (Bremelanotide) Accelerated Titration: Doses, Schedule, and Safety

HealthRX.com

Vyleesi has one dose and no titration schedule

Print or save as PDF

Key numbers

  • 1.75 mgLabeled Vyleesi dose: a single 1.75 mg subcutaneous dose taken as neededSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 24 hoursMinimum gap between Vyleesi doses: no more than one dose within this periodSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 8 doses per monthMonthly dose limit: the label says more than this amount is not recommendedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Nausea rate in Vyleesi-treated women in pooled phase 3 trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • Approved product / Vyleesi 1.75 mg prefilled autoinjector [1]
  • Approved dose / 1.75 mg subcutaneous, as needed [1]
  • Timing / at least 45 minutes before anticipated sexual activity [1]
  • Limits / no more than one dose per 24 hours; more than 8 doses a month not recommended [1]
  • Lower doses studied / 0.75, 1.25 and 1.75 mg as fixed doses in phase 2 [2]
  • Nausea / 40% overall; 21% after the first dose, about 3% later [1]

What the label says

The label gives one dose: 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. It says patients should not administer more than one dose within 24 hours, and that administering more than 8 doses per month is not recommended [1]. Vyleesi is self-administered with a prefilled autoinjector pen [1]. The label describes no lower starting dose or step-up schedule [1].

Questions worth asking

Choose the questions you want to keep

Where 0.75 and 1.25 mg come from

A 12-week phase 2 dose-finding trial randomized premenopausal women with female sexual dysfunction to placebo or bremelanotide 0.75, 1.25 or 1.75 mg subcutaneously as desired, with efficacy data on 327 patients [2]. Nausea, flushing and headache were the reported adverse events [2]. The trial compared fixed doses, not a step-up sequence [2]. The phase 3 registration trials used 1.75 mg as needed for 24 weeks [1][3].

Tolerability at the labeled dose

In the pooled phase 3 trials, nausea occurred in 40.0% of Vyleesi-treated women versus 1.3% on placebo; it was reported by 21% after the first dose and about 3% after later doses [1]. In a phase 4 single-dose study of 228 healthy women, 8 mg oral ondansetron taken 30 minutes before a 1.75 mg dose did not reduce nausea, and the label says this pre-treatment is not recommended [1].

Blood pressure and dosing frequency

The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with values usually back to baseline within 12 hours [1]. In an 8-day study of 127 women, mean daytime rises were 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. The label says to consider cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment; it says Vyleesi is not recommended for patients at high risk of cardiovascular disease and is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1]. On dosing frequency, the label says more frequent dosing increases the risk of focal hyperpigmentation and the length of time per month when blood pressure is increased [1]. Focal hyperpigmentation was reported in 1% of patients given up to 8 doses a month in the placebo-controlled phase 3 trials, versus none on placebo [1].

Compounded products

Compounded and research-use PT-141 products are not Vyleesi and are not FDA-approved; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [4][5].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the label, what is the dosing schedule for Vyleesi?

Question 1 of 5

Score: 0 right, 0 of 5 answered

How many doses of PT-141 can you use in a month?
The label says not to administer more than one dose within 24 hours, and that more than 8 doses per month is not recommended [1]. It says more frequent dosing increases the risk of focal hyperpigmentation and the length of time per month when blood pressure is increased [1].
Does ondansetron prevent nausea from bremelanotide?
No. In a phase 4 study of 228 healthy women, 8 mg of oral ondansetron taken 30 minutes before a 1.75 mg dose did not reduce nausea, and the label says pre-treatment with ondansetron is not recommended [1].
Is compounded PT-141 the same as Vyleesi?
No. Vyleesi is the FDA-approved bremelanotide product; compounded and research-use PT-141 products are not FDA-approved, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [4][5].
Show all 5 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-37.
  3. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
  4. Official web page.
  5. Compounding and the FDA: Questions and Answers | FDA.
PT-141: evidence summary chart
Image: HealthRX.com. Full PT-141 guide and sources at healthrx.com/titration-pt-141.